From Kuttu to Jawar: Indian grains and their english names
Tired of too many ads? go ad free now
While some are known around the world, others are still waiting to be noticed beyond our local markets. Here's a look at five Indian grains, their English names and why they belong in your daily meals.
Kuttu – Buckwheat
Kuttu is a popular fasting grain in many Indian households. In English, it's called buckwheat. Despite the name, it has nothing to do with wheat and is completely gluten-free. It helps boost energy, keeps you full for longer and is known to be easy on digestion.
From soft kuttu rotis to crispy pakoras, this one brings both taste and balance to your meals, making it a smart choice beyond just festive days.
Jowar – Sorghum
Jowar, or sorghum, is one of the most ancient grains in the world. It's high in fibre, packed with antioxidants and makes for a perfect gluten-free alternative to wheat. Soft, warm jowar rotis pair beautifully with sabzis and chutneys. You'll also find it used in porridge and laddoos across different states.
It's hearty, filling and naturally cooling in summer.
Bajra – Pearl millet
Bajra goes by the name pearl millet in English. It's a winter staple in many parts of India, especially in Rajasthan and Gujarat. Known for its warming nature, bajra helps improve gut health and keeps you feeling full and energised. You can make bhakris, theplas or even bajra khichdi. It's the kind of grain that brings both flavour and strength to the table.
Ragi – Finger millet
Ragi, also known as finger millet, is one of the best grains for growing kids, elders and everyone in between.
Tired of too many ads? go ad free now
It's packed with calcium and iron and helps support brain development and bone strength. You'll find it used in dosas, idlis, laddoos and even in porridges for babies. It has a naturally earthy flavour that blends beautifully into both sweet and savoury dishes.
Rajgira – Amaranth
Rajgira, or amaranth, is a small but mighty grain often used during fasting. It's high in protein, minerals and antioxidants. Whether popped like popcorn or made into laddoos and rotis, rajgira adds texture and nutrition to every bite. Its nutty flavour works well in modern granola bars too.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
Experts call for inclusion of Chronic Kidney Disease in national NCD programme
Hyderabad-based dialysis care network, NephroPlus, has urged policymakers to include Chronic Kidney Disease (CKD) screening in India's flagship National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), as it released a white paper highlighting the rising burden of CKD across India and neighbouring countries. Speaking at a media briefing in Hyderabad on Tuesday, NephroPlus Group CEO Rohit Singh said the findings of the white paper and a large-scale screening initiative make a strong case for integrating CKD testing, particularly serum creatinine and urine albumin-to-creatinine ratio (ACR), into existing government-led screenings for hypertension and diabetes. 'The burden is silent but severe. CKD needs to be part of India's NCD strategy immediately,' he said. The paper is based on data from a kidney health screening campaign conducted in the lead-up to World Kidney Day in March. The campaign spanned 30 locations across India, the Philippines, and Uzbekistan, and covered 12 Indian States. A total of 10,501 persons pledged for kidney health awareness, of whom more than 5,000 underwent free serum creatinine and estimated glomerular filtration rate (eGFR) tests. NephroPlus found that several Indian States reported high prevalence of CKD risk factors. Jharkhand topped the list, followed by Haryana and Uttarakhand, Andhra Pradesh, Bihar, Delhi, Karnataka, Maharashtra, Uttar Pradesh, Telangana, Gujarat and Rajasthan. NephroPlus co-founder Kamal D. Shah stressed the economic and emotional toll of dialysis. 'Dialysis is not just a treatment; it is a lifelong ordeal that drains families physically, emotionally and financially. Our data shows that investing ₹1 in prevention saves ₹10 to ₹15 in future dialysis costs,' he said.
Time of India
3 hours ago
- Time of India
Pharma lobby flags 'cumbersome' export rule, seeks change
New Delhi: A significant dip in exports has prompted pharma lobby groups to raise a demand for changing the centralised no-object certification (NOC) provision for drug exports . The provision, which requires pharma companies to seek an approval from the national regulatory agency of the importing country or an NOC from the Indian regulator for shipments, has resulted in a drop in exports and diverted trade to other nations, industry executives told ET. The issue was raised in a meeting held on Monday at Niti Aayog . "Pharma exports have suffered due to the mismatch or an anomaly in newly introduced regulatory standards by the drug regulatory authority of India," said a person who attended the meeting. In early March, the Drugs Controller General of India (DCGI) updated the export NOC checklist in the wake of events such as the controversy over a Mumbai-based drugmaker allegedly exporting addictive opioid drugs to West African nations such as Ghana and Nigeria. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like What the Market May Be Getting Wrong About Nvidia Seeking Alpha Read More Undo However, the stringent norms have started hurting exports, industry insiders said. "Taking approvals from different regulatory bodies has only made the whole process cumbersome," the person cited above said. He noted that medicines are manufactured depending on the patient population construct. Live Events For example, Dolo and other paracetamol tablets are approved in India in strengths of 325mg, 500 mg and 650 mg while in Nigeria, it's approved for a strength of 1,000 mg. To manufacture and export that, Indian drugmakers now require an NOC from Nigerian authorities. The lobby groups have urged the government to review the provision as, according to them, this would divert trade to other nations with less stringent regulations. "Such a condition has imposed an undue burden on Indian exporters, potentially stifling innovation and hindering the export of unapproved/banned products especially for the MSME pharmaceutical sector, which is under tremendous strain with respect to compliance to domestic and international guidelines and trade barriers (tariffs & non-tariffs),' an industry expert said on condition of anonymity. The Niti Aayog had called pharma experts to undertake an analysis of the current state of the industry, to understand the challenges faced by drugmakers and initiatives taken by them to ensure production of safe and effective products. Nikkhil K Masurkar, chief executive of Entod Pharmaceuticals, said the official think tank's call for a quality overhaul is both "timely and necessary." "While India has made remarkable strides as a global pharma hub, maintaining consistent, internationally acceptable quality standards remains a key challenge, especially among MSME companies," he said. "The root of the problem often lies not in intent, but in outdated infrastructure, fragmented regulatory enforcement, and insufficient technical training," Masurkar said. "To produce world-class medicines, we must invest in continuous quality improvement, digitalise compliance systems, and empower our MSME sector with both financial and technical support."
Time of India
3 hours ago
- Time of India
Gujarat scientist in US Developing Tech for effective treatment of brain diseases
Vadodara: A Gujarati scientist, native of Vadodara, is working on a technology that would deliver drugs in a larger quantity inside the brain. Dr Ishan Shah is a key member of the US team that has already got intellectual property (IP) rights for the research. "It's a long process, but this technology will help those suffering from any kind of brain diseases. Currently, only 0.1% of any drug given for brain ailments is able to enter the brain. It is a challenge to deliver the drugs inside the brain, which blocks a major quantity," explained Shah, who works for a private biotech company in Boston. "We are developing antibodies that will increase the quantity of drugs delivered inside the brain from 0.1% to 1%. This will increase the efficacy of drugs. We discovered a protein that captures the drug and puts it inside the brain. Our firm even got IP rights. Such an experiment is being undertaken for the first time," Shah told TOI over the phone from the US. The team's work has also been published by the Royal Society of Chemistry. Shah, 38, was also a member of the team working on an effective drug for Alzheimer's, which currently has no cure. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Launch by L&T – 3 & 4 BHKs Near Viviana L&T Evara Heights Enquire Now Undo "We are trying to find out the reason behind the spike of a certain protein that causes Alzheimer's. If we manage to ascertain the reason and control the accumulation of this protein, we will be able to delay the advancement of Alzheimer's. The drug is already in the trial stage," Shah, a senior scientist, added. He is the only Indian in the team working on this drug. A student of Bright School in Karelibaug, Shah completed his Bachelor's in Pharmacy from A R College of Pharmacy in Vidyanagar in 2009. He then pursued a Master's in Pharmacy at the University of Toledo in Ohio. "I wanted to stay in the field of drug discovery, so I pursued a PhD in pharmaceutical chemistry from the University of Kansas in 2011. Then I shifted to Boston, where I worked with a small firm before joining my current company in 2020," said Shah, who is settled in Boston with his wife, Kinjal.
